+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cytomegalovirus infection in bone marrow transplant recipients: use of intravenous gamma globulin as a prophylactic and therapeutic agent



Cytomegalovirus infection in bone marrow transplant recipients: use of intravenous gamma globulin as a prophylactic and therapeutic agent



Transplantation Proceedings 21(1 Pt 3): 3095-3096




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 030784819

Download citation: RISBibTeXText

PMID: 2539686


Related references

Prevention of cytomegalovirus infection in bone marrow transplant recipients by prophylaxis with an intravenous, hyperimmune cytomegalovirus globulin. Birth Defects Original Article Series 20(1): 327-344, 1984

Prophylaxis of cytomegalovirus infection in bone marrow transplant recipients by hyper immune cytomegalovirus gamma globulin. International Association Of Biological Standardization (edelopments In Biological Standardization, Vol. 52. Herpesvirus Of Man And Animal: Standardization Of Immunological Procedures; Proceedings Of A Symposium; Lyon, France, Dec. 7-9, . X 571p. S. Karger: Basel, Switzerland; New York, N.y., Usa. Illus. P501-514, 1982, 1983

Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients. American Journal of Medicine 76(3a): 134-141, 1984

One week intervals of intravenous gamma globulin treatment to prevent a cytomegalovirus antibody decrease in bone marrow transplant recipients. Abstracts of the Annual Meeting of the American Society for Microbiology 87: 109, 1987

Preliminary data of a controlled trial of intravenous hyperimmune globulin in the prevention of cytomegalovirus infection in bone marrow transplant recipients. Transplantation Proceedingspart 1: 468-469, 1985

No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. Bone Marrow Transplantation 19(3): 233-236, 1997

Cytomegalovirus infection in heart transplant recipients: preliminary results of a controlled trial of intravenous gamma globulin. Journal of Clinical Immunology 2(2 Suppl.): 36s-41s, 1982

Positive direct antiglobulin tests associated with intravenous gamma globulin use in bone marrow transplant recipients. Transplantation 41(5): 663-664, 1986

Prophylaxis of CMV infection in bone marrow transplant recipients by hyperimmune CMV gamma-globulin. Developments in Biological Standardization 52: 501-513, 1982

Preliminary data of a controlled trial of intravenous hyperimmunoglobulin in the prevention of cytomegalovirus infection in bone marrow transplant recipients. International Society Of Blood Transfusion Abstracts Of The Congress Of The International Society Of Blood Transfusion, No 18 Symposium; Munich, West Germany, July 22-27, 240p S Karger: Basel, Switzerland; New York, N Y , Usa Illus Paper 27, 1984

The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients. Bone Marrow Transplantation 2(2): 141-147, 1987

Cytomegalovirus infection in renal transplant recipients report 4. cytomegalovirus neutralizing antibody titers of gamma globulin and interferon. Nishinihon Journal of Urology 48(3): 717-721, 1986

Prophylactic application of cytomegalovirus immune globulin in recipients of allogeneic bone marrow transplantations. Bone Marrow Transplantation 2(Suppl. 1): 270, 1987

Prophylactic application of an anti-cytomegalovirus hyperimmunoglobulin in allogeneic bone marrow transplant recipients. Haematology and Blood Transfusion 30: 541-544, 1987

Comparative trial of intravenous cytomegalovirus globulin and seronegative blood products for the prevention of primary cytomegalovirus infection following marrow transplant. Clinical Research 33(2 Part 1): 395A, 1985